All In Biotech

Drug Trial Radar · NCT03299244

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

Last checked: Nov 20, 2026Latest source record: Apr 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 637 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

637

Actual

Start

May 15, 2018

Primary completion

Apr 8, 2020

Study completion Apr 8, 2020

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by \> 30% from baseline among participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.

Conditions

  • Secondary Hyperparathyroidism
  • Chronic Kidney Disease

Interventions

  • EtelcalcetideDrug

    Administered intravenously three times per week.

  • CinacalcetDrug

    Cinacalcet administered orally once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority AnalysisTime frame: Baseline and the efficacy assessment phase (EAP; defined as weeks 20 to 27, inclusive).

Locations

90 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Beijing, Beijing Municipality, China

  • Research Site

    Lanzhou, Gansu, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Guangzhou, Guangdong, China

  • Research Site

    Shenzhen, Guangdong, China

  • Research Site

    Zhanjiang, Guangdong, China

  • Research Site

    Nanning, Guangxi, China

  • Research Site

    Nanning, Guangxi, China

  • Research Site

    Zhengzhou, Henan, China

  • Research Site

    Zhengzhou, Henan, China

  • Research Site

    Wuhan, Hubei, China

  • Research Site

    Wuhan, Hubei, China

  • Research Site

    Wuhan, Hubei, China

  • Research Site

    Changsha, Hunan, China

  • Research Site

    Changsha, Hunan, China

  • Research Site

    Changzhou, Jiangsu, China

  • Research Site

    Nanjing, Jiangsu, China

  • Research Site

    Nanjing, Jiangsu, China

  • Research Site

    Wuxi, Jiangsu, China

  • Research Site

    Changchun, Jilin, China

  • Research Site

    Changchun, Jilin, China

  • Research Site

    Dalian, Liaoning, China

  • Research Site

    Dalian, Liaoning, China

  • Research Site

    Dalian, Liaoning, China

  • Research Site

    Shenyang, Liaoning, China

  • Research Site

    Shenyang, Liaoning, China

  • Research Site

    Xi'an, Shaanxi, China

  • Research Site

    Qingdao, Shandong, China

  • Research Site

    Shanghai, Shanghai Municipality, China

  • Research Site

    Shanghai, Shanghai Municipality, China

  • Research Site

    Shanghai, Shanghai Municipality, China

  • Research Site

    Shanghai, Shanghai Municipality, China

  • Research Site

    Taiyuan, Shanxi, China

  • Research Site

    Chengdu, Sichuan, China

  • Research Site

    Chengdu, Sichuan, China

  • Research Site

    Tianjin, Tianjin Municipality, China

  • Research Site

    Tianjin, Tianjin Municipality, China

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.